Utah Medical Products (UTMD) Liabilities and Shareholders Equity (2010 - 2026)

Utah Medical Products' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $124.4 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 1.52% year-over-year to $124.4 million; the TTM figure through Mar 2026 stood at $489.7 million (down 2.99% YoY), while the FY2025 annual figure was $122.5 million, changed 0.0% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $124.4 million, up from $122.5 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $135.5 million in Q4 2023, with the low at $116.1 million in Q2 2022.
• The 5-year median for Liabilities and Shareholders Equity is $123.9 million (2022), against an average of $125.5 million.
• The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity advanced 12.33% in 2023, then fell 9.54% in 2025.
• Utah Medical Products' Liabilities and Shareholders Equity stood at $123.9 million in 2022, then advanced by 9.35% to $135.5 million in 2023, then retreated by 9.54% to $122.5 million in 2024, then advanced by 0.0% to $122.5 million in 2025, then increased by 1.5% to $124.4 million in 2026.
• Business Quant data shows UTMD's Liabilities and Shareholders Equity at $124.4 million in Q1 2026, $122.5 million in Q4 2025, and $122.0 million in Q3 2025.